US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CRO Concept

1,900.11

+39.972.15%

Number of Gainers:2

Number of Losers:- -

Number of Flat:1

PE:- -

High:1,917.02

Open:1,860.74

Low:1,860.74

Close:1,860.14

Volume:2.23M

Turnover:474.18M

Market Cap:48.19B

Float Cap:46.10B

Loading ...

Ligand Pharmaceuticals Expected to Issue Conservative 2026 Outlook at Upcoming Investor Day, RBC Says

MT Newswires Live

Charles River Q3 Adjusted EPS USD 2.43 Vs. IBES Estimate USD 2.34

Charles River Exec Says Co Is Looking to Expand Its Services Portfolio in China - Jefferies Healthcare Conf

THOMSON REUTERS

Charles River: SEC concluded inquiry into company, not recommeding enforcement

SEC Ends Probe Into Charles River Laboratories With No Enforcement Action

Charles River Laboratories-Investigation Was About Inquiry Requesting to Give Information Related to Sourcing Non-Human Primates & Related Disclosures

THOMSON REUTERS

Charles River Laboratories International Inc - SEC Concludes Investigation, No Action Against Charles River Labs - SEC Filing

THOMSON REUTERS

Charles River Laboratories Presents at Jefferies Global Healthcare Conference

Charles River Laboratories International Inc : Argus Research Raises to Buy From Hold

THOMSON REUTERS

IQVIA Holdings Inc. Files Initial Beneficial Ownership Statement for Director William G. Kaelin, Jr

IQVIA Holdings Inc : Bmo Initiates Coverage With Outperform Rating; Price Target $260

THOMSON REUTERS

Applied Therapeutics Reports Third Quarter 2025 Financial Results

Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London

Elite Pharmaceuticals Receives FDA Approval for Generic Requip XL

Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

IQVIA (IQV): Assessing Valuation After Nobel Laureate Dr. Kaelin Joins Board

Simply Wall St.

Charles River Labs Is Maintained at Equal-Weight by Morgan Stanley

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4530/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4530","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4530\",,,,,undefined,":{"symbol":"BK4530","market":"US","secType":"PLATE","nameCN":"CRO Concept","latestPrice":1900.1107,"timestamp":1764104399997,"preClose":1860.1426,"halted":0,"volume":2228560,"delay":0,"changeRate":0.021487,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":39.96814,"latestTime":"11-25 16:00:00 EST","open":1860.7372,"high":1917.0189,"low":1860.7372,"amount":474176631.095874,"amplitude":0.030257,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1764147600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":4.866572,"peRate":38.769134,"turnoverRate":0.010608,"increases":2,"decrements":0,"flats":0,"marketCap":48189214720,"floatMarketCap":46103736320},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4530\",,,,,undefined,":{"symbol":"BK4530","high":1917.0189,"amplitude":0.030257,"preClose":1860.1426,"low":1860.7372,"pbRate":"4.866572","latestPrice":1900.1107,"volume":2228560,"delay":0,"open":1860.7372,"prevYearClose":1673.3123,"prevWeekClose":1833.2347,"prevMonthClose":1800.054,"prevQuarterClose":1576.7454,"fiveDayClose":1772.1769,"twentyDayClose":1826.2722,"sixtyDayClose":1544.6295,"secType":"PLATE","market":"US","turnoverRate":0.010608,"peRate":38.769134,"marketCap":48189214720,"floatMarketCap":46103736320,"timestamp":1764104399997,"nameCN":"CRO Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4530\",,,,undefined,":{"bkCode":"BK4530","up":2,"down":0,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4530\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2586606477","title":"Ligand Pharmaceuticals Expected to Issue Conservative 2026 Outlook at Upcoming Investor Day, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2586606477","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586606477?lang=en_us&edition=fundamental","pubTime":"2025-11-26 00:19","pubTimestamp":1764087588,"startTime":"0","endTime":"0","summary":"Ligand Pharmaceuticals  is expected to issue conservative 2026 guidance at its upcoming investor day, with updates to its royalty outlook anchored by Zelsuvmi and the upcoming Filspari regulatory decision, RBC Capital markets said in a note Tuesday.RBC expects 2026 adjusted core EPS of $7.91 and revenue of $251 million.The company's recent launch of Zelsuvmi has shown \"strong momentum\" with IQVIA  monthly prescriptions rising from 113 in July to 1,291 in October, RBC noted.Filspari is a major near-term catalyst with an upcoming regulatory decision in January 2026 and RBC estimates the therapy could contribute roughly $148 million in royalty receipts by 2030.The company's investor day is scheduled on Dec. 9.RBC reiterated its outperform rating on Ligand Pharmaceuticals and set a $234 price target.Price: 206.29, Change: -0.60, Percent Change: -0.29","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0198837287.USD","BK4139","IE0009354923.USD","LU0130518102.USD","BK4585","LU1201861249.SGD","BK4530","LGND","LU1791710400.SGD","BK4588","LU1559883803.SGD","LU0528227936.USD","LU0566484027.USD","LU0130517989.USD","LU0980610538.SGD","LU1989764664.SGD","BK4007","LU1989764748.USD","LU0130103400.USD","LU0648000940.SGD","LU0130102774.USD","LU1261432733.SGD","IQV","LU1791710582.SGD","LU0648001328.SGD","LU1201861165.SGD","LU0477156797.USD","LU0477156953.USD","LU0882574055.USD","BK4121"],"gpt_icon":0},{"id":"2584850926","title":"Charles River Q3 Adjusted EPS USD 2.43 Vs. IBES Estimate USD 2.34","url":"https://stock-news.laohu8.com/highlight/detail?id=2584850926","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584850926?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:38","pubTimestamp":1763570307,"startTime":"0","endTime":"0","summary":"Nov 05 (Reuters) - Charles River Q3 revenue USD 1,000 million vs. IBES estimate USD 990.8 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 05-NOV-202512:00:47.577 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSDbjC6P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0757428866.USD","CRL","BK4585","BK4530","LU0390134368.USD","BK4588","IE00BFMHRM44.USD","LU1815336091.USD","BK4121"],"gpt_icon":0},{"id":"2584210931","title":"Charles River Exec Says Co Is Looking to Expand Its Services Portfolio in China - Jefferies Healthcare Conf","url":"https://stock-news.laohu8.com/highlight/detail?id=2584210931","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584210931?lang=en_us&edition=fundamental","pubTime":"2025-11-18 19:48","pubTimestamp":1763466537,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nFWN3WU0GB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0390134368.USD","BK4585","IE00BFMHRM44.USD","LU0757428866.USD","BK4530","LU1815336091.USD","CRL","BK4121","BK4588"],"gpt_icon":0},{"id":"2584626856","title":"Charles River: SEC concluded inquiry into company, not recommeding enforcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2584626856","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584626856?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:16","pubTimestamp":1763385385,"startTime":"0","endTime":"0","summary":"In a regulatory filing, Charles River (CRL) said that on May 16, 2023, the company received an inquiry from the Enforcement Division of the U.S. Se...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/charles-river-sec-concluded-inquiry-into-company-not-recommeding-enforcement-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/charles-river-sec-concluded-inquiry-into-company-not-recommeding-enforcement-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4530","LU0757428866.USD","BK4585","LU0390134368.USD","LU1815336091.USD","CRL","BK4588","BK4121","IE00BFMHRM44.USD"],"gpt_icon":0},{"id":"2584973625","title":"SEC Ends Probe Into Charles River Laboratories With No Enforcement Action","url":"https://stock-news.laohu8.com/highlight/detail?id=2584973625","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584973625?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:07","pubTimestamp":1763384859,"startTime":"0","endTime":"0","summary":"Charles River Laboratories International Inc. announced that the U.S. Securities and Exchange Commission  has concluded its investigation into the company's sourcing of non-human primates and related disclosures. The SEC informed the company that it does not intend to recommend any enforcement action. Additionally, an independent investigation conducted by the company's Audit Committee also concluded with no material findings.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Charles River Laboratories International Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 17, 2025, and ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL8CyjrM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","LU0390134368.USD","BK4585","IE00BFMHRM44.USD","LU1815336091.USD","LU0757428866.USD","BK4588","CRL","BK4530"],"gpt_icon":0},{"id":"2584625488","title":"Charles River Laboratories-Investigation Was About Inquiry Requesting to Give Information Related to Sourcing Non-Human Primates & Related Disclosures","url":"https://stock-news.laohu8.com/highlight/detail?id=2584625488","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584625488?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:07","pubTimestamp":1763384838,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nFWN3WT0UF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4121","BK4530","LU0390134368.USD","CRL","IE00BFMHRM44.USD","LU0757428866.USD","LU1815336091.USD","BK4588"],"gpt_icon":0},{"id":"2584259246","title":"Charles River Laboratories International Inc - SEC Concludes Investigation, No Action Against Charles River Labs - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2584259246","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584259246?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:07","pubTimestamp":1763384838,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nFWN3WT0UF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BFMHRM44.USD","LU0757428866.USD","LU1815336091.USD","BK4121","BK4530","LU0390134368.USD","BK4585","BK4588","CRL"],"gpt_icon":0},{"id":"2584255256","title":"Charles River Laboratories Presents at Jefferies Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2584255256","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584255256?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:01","pubTimestamp":1763384501,"startTime":"0","endTime":"0","summary":"Charles River Laboratories International Inc. announced that it will present at the Jefferies Global Healthcare Conference in London on Tuesday, November 18th, at 11:30 a.m. GMT. During the event, company management will provide an overview of Charles River's strategic focus, business developments, and recent trends. A live webcast of the presentation will be available on the Investor Relations section of the company's website, with a replay accessible for at least two weeks following the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Charles River Laboratories International Inc. published the original content used to generate this news brief via Business Wire  on November 17, 2025, and is solely responsible for the information ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL7Qj0PX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRL","IE00BFMHRM44.USD","BK4585","BK4588","BK4121","LU0757428866.USD","BK4530","LU1815336091.USD","LU0390134368.USD"],"gpt_icon":0},{"id":"2584623403","title":"Charles River Laboratories International Inc : Argus Research Raises to Buy From Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2584623403","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584623403?lang=en_us&edition=fundamental","pubTime":"2025-11-17 20:49","pubTimestamp":1763383763,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nFWN3WT1GD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0757428866.USD","BK4530","IE00BFMHRM44.USD","BK4121","BK4585","LU0390134368.USD","LU1815336091.USD","CRL","BK4588"],"gpt_icon":0},{"id":"2583682065","title":"IQVIA Holdings Inc. Files Initial Beneficial Ownership Statement for Director William G. Kaelin, Jr","url":"https://stock-news.laohu8.com/highlight/detail?id=2583682065","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583682065?lang=en_us&edition=fundamental","pubTime":"2025-11-15 06:03","pubTimestamp":1763157804,"startTime":"0","endTime":"0","summary":"IQVIA Holdings Inc. has filed an initial statement of beneficial ownership  with the U.S. Securities and Exchange Commission. The filing lists William G. Kaelin, Jr. as a director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IQVIA Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 14, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL2Zgtz7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0477156953.USD","LU1989764664.SGD","BK4588","LU0980610538.SGD","LU0198837287.USD","LU0648001328.SGD","LU0882574055.USD","LU1791710582.SGD","LU0528227936.USD","LU1201861249.SGD","LU0130102774.USD","LU1791710400.SGD","LU0130517989.USD","IQV","LU0648000940.SGD","BK4585","LU0477156797.USD","BK4121","LU1261432733.SGD","LU1989764748.USD","LU1201861165.SGD","BK4530","LU0130518102.USD","LU0130103400.USD"],"gpt_icon":0},{"id":"2583562167","title":"IQVIA Holdings Inc : Bmo Initiates Coverage With Outperform Rating; Price Target $260","url":"https://stock-news.laohu8.com/highlight/detail?id=2583562167","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583562167?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:12","pubTimestamp":1763035975,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nFWN3WP1CH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0130102774.USD","IQV","LU1791710582.SGD","LU1989764748.USD","LU0980610538.SGD","LU0882574055.USD","BK4588","LU0130103400.USD","LU0198837287.USD","BK4585","LU0477156953.USD","LU1201861165.SGD","LU1791710400.SGD","LU0528227936.USD","BK4121","LU1989764664.SGD","LU0130517989.USD","LU1261432733.SGD","LU0130518102.USD","BK4530","LU0477156797.USD","LU0648001328.SGD","LU0648000940.SGD","LU1201861249.SGD"],"gpt_icon":0},{"id":"2583620455","title":"Applied Therapeutics Reports Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2583620455","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583620455?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:00","pubTimestamp":1763035200,"startTime":"0","endTime":"0","summary":"– Update on regulatory strategy for govorestat for the treatment of CMT-SORD following receipt of Type C meeting minutes – Meeting scheduled with the FDA in 4Q 2025 to discuss govorestat for the treat","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/13/3187173/0/en/Applied-Therapeutics-Reports-Third-Quarter-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0390134368.USD","LU1815336091.USD","BK4135","CRL","BK4530","LU0757428866.USD","BK4007","ARI","BK4585","BK4539","BK4110","BK4139","BK4588","BK4121","IE00BFMHRM44.USD","LENZ","CNS"],"gpt_icon":0},{"id":"2583258504","title":"Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London","url":"https://stock-news.laohu8.com/highlight/detail?id=2583258504","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583258504?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:05","pubTimestamp":1762981500,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md., Nov.  12, 2025  (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of c","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/12/3186793/19871/en/Supernus-to-Participate-in-the-2025-Jefferies-Global-Healthcare-Conference-in-London.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","CNS","LU1169589451.USD","BK4581","BK4588","LU0029874061.USD","XBI","XLV","BK4023","PPD","ADHD","BK4585","PD","BK4121","BK4137","BK4135","BK4530","LU0128526141.USD","BK4561","LU1169590202.USD","HCSG"],"gpt_icon":0},{"id":"2582373018","title":"Elite Pharmaceuticals Receives FDA Approval for Generic Requip XL","url":"https://stock-news.laohu8.com/highlight/detail?id=2582373018","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582373018?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:02","pubTimestamp":1762948976,"startTime":"0","endTime":"0","summary":"Elite Pharmaceuticals Inc. announced that it has received approval from the US Food and Drug Administration  for its Abbreviated New Drug Application  for a generic version of Requip XL  in 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg strengths. The product, intended for the treatment of Parkinson's disease symptoms, will be marketed under the Elite Laboratories, Inc. label. According to IQVIA, the branded product and its equivalents recorded US sales of $10 million for the twelve months ending September 2025. The approval is exclusive to Elite Pharmaceuticals Inc.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elite Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile  on November 12, 2025, and is sol","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDLbjJWzB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1201861165.SGD","LU0130102774.USD","BK4588","LU0130518102.USD","BK4121","LU1791710582.SGD","LU0198837287.USD","BK4530","LU0130103400.USD","LU1261432733.SGD","LU0477156797.USD","LU1989764748.USD","LU0882574055.USD","LU0648001328.SGD","LU0980610538.SGD","LU0130517989.USD","ELTP","BK4007","LU0528227936.USD","LU0477156953.USD","LU0648000940.SGD","LU1791710400.SGD","BK4585","LU1989764664.SGD","IQV","LU1201861249.SGD"],"gpt_icon":0},{"id":"2582376431","title":"Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2582376431","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582376431?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:01","pubTimestamp":1762948860,"startTime":"0","endTime":"0","summary":"PDUFA Target Date of December 13, 2025 for CARDAMYST (etripamil) Nasal Spray in Paroxysmal Supraventricular Tachycardia (PSVT)  Promotional Launch Plans Set with Quick-Start Capability Upon Potential ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/12/3186091/0/en/Milestone-Pharmaceuticals-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Regulatory-and-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0757428866.USD","BK4121","LU1815336091.USD","CRL","BK4588","BK4530","IE00BFMHRM44.USD","BK4585","LU0390134368.USD"],"gpt_icon":0},{"id":"2582373124","title":"IQVIA (IQV): Assessing Valuation After Nobel Laureate Dr. Kaelin Joins Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2582373124","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582373124?lang=en_us&edition=fundamental","pubTime":"2025-11-12 18:27","pubTimestamp":1762943237,"startTime":"0","endTime":"0","summary":"IQVIA Holdings has announced that Dr. William G. Kaelin Jr., Nobel Prize-winning physician-scientist, is joining its board of directors. Investors may view this move as a way to strengthen the company’s scientific leadership and strategic direction.\nSee our latest analysis for IQVIA Holdings.\nIQVIA Holdings' 14.9% share price gain over the past three months hints at growing investor enthusiasm, likely sparked by fresh scientific leadership and a renewed sense of direction. However, the 1-year...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/137473239-main-header/1756256222159","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/137473239-main-header/1756256222159"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-iqv/iqvia-holdings/news/iqvia-iqv-assessing-valuation-after-nobel-laureate-dr-kaelin","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-iqv/iqvia-holdings/news/iqvia-iqv-assessing-valuation-after-nobel-laureate-dr-kaelin","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1791710582.SGD","LU0980610538.SGD","LU0130103400.USD","LU1201861249.SGD","LU0198837287.USD","IQV","LU0130518102.USD","BK4585","LU0882574055.USD","LU1989764748.USD","LU1201861165.SGD","LU1261432733.SGD","BK4121","LU0648000940.SGD","LU0648001328.SGD","LU0477156953.USD","BK4530","LU0130517989.USD","LU0477156797.USD","LU1791710400.SGD","LU1989764664.SGD","BK4588","LU0528227936.USD","LU0130102774.USD"],"gpt_icon":0},{"id":"2582739556","title":"Charles River Labs Is Maintained at Equal-Weight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2582739556","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582739556?lang=en_us&edition=fundamental","pubTime":"2025-11-12 00:46","pubTimestamp":1762879560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 11, 2025 11:46 ET (16:46 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","LU0390134368.USD","BK4585","IE00BFMHRM44.USD","LU1815336091.USD","LU0757428866.USD","BK4588","CRL","BK4530"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":17,"code":"91000000","status":"200"}]}}